Stephen R. Petteway, Jr. regularly asks himself, "If I were a patient, what would I want to see in my products?" Unmet patient needs are his primary motivator, and he encourages the same attitude among the roughly 330 scientists, engineers, and technicians he directs at Talecris Biotherapeutics' plant in Clayton, NC, as well as its research and testing laboratories in Raleigh and Research Triangle Park. With more than 25 years in the pharmaceutical business, the last 11 of them with Bayer and Talecris, he brings a wealth of knowledge and experience to developing protein therapies, and moving them out of the lab and safely into the clinic as quickly as possible.
Known in the scientific community for pioneering work on HIV and pathogen safety in blood plasma-based medicines, Petteway is the senior vice president of R&D at Talecris and has been chairperson of the Plasma Protein Therapies Association's plasma-safety steering ...